CymaBay Therapeutics (NASDAQ:CBAY) was downgraded by stock analysts at Oppenheimer to a “hold” rating in a research note issued on Monday, TipRanks reports.
Several other analysts have also recently weighed in on the company. Cantor Fitzgerald set a $20.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 18th. ValuEngine raised CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, November 4th. Stifel Nicolaus cut CymaBay Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Monday. HC Wainwright reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a report on Wednesday, November 6th. Finally, BidaskClub raised CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. CymaBay Therapeutics has an average rating of “Buy” and a consensus target price of $12.07.
Shares of NASDAQ:CBAY traded down $4.24 on Monday, hitting $1.31. The company’s stock had a trading volume of 958,202 shares, compared to its average volume of 638,625. The company has a 50-day simple moving average of $5.02 and a 200 day simple moving average of $7.03. CymaBay Therapeutics has a 1 year low of $4.23 and a 1 year high of $14.00. The company has a market capitalization of $359.31 million, a PE ratio of -1.04 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.12 and a quick ratio of 13.12.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, equities research analysts expect that CymaBay Therapeutics will post -1.51 earnings per share for the current fiscal year.
In other CymaBay Therapeutics news, CEO Sujal Shah acquired 5,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the acquisition, the chief executive officer now owns 111,900 shares in the company, valued at approximately $618,807. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 11,900 shares of company stock valued at $59,600. Company insiders own 4.20% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CBAY. Bank of Montreal Can lifted its stake in shares of CymaBay Therapeutics by 1,372.0% in the 2nd quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,311 shares during the period. Tower Research Capital LLC TRC purchased a new position in CymaBay Therapeutics during the third quarter valued at $61,000. Cambridge Investment Research Advisors Inc. purchased a new position in CymaBay Therapeutics during the second quarter valued at $80,000. SG Americas Securities LLC purchased a new position in CymaBay Therapeutics during the third quarter valued at $85,000. Finally, Aperio Group LLC purchased a new position in CymaBay Therapeutics during the second quarter valued at $104,000. Institutional investors own 99.49% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Read More: Why Net Income is Important to Investors